165 related articles for article (PubMed ID: 18062504)
1. [Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?].
Perey L; Zaman K
Rev Med Suisse; 2007 Oct; 3(130):2406, 2408-10, 2412. PubMed ID: 18062504
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
Sulkes A
Isr Med Assoc J; 2005 Apr; 7(4):257-61. PubMed ID: 15847208
[TBL] [Abstract][Full Text] [Related]
3. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
4. Update on aromatase inhibitors in breast cancer.
Gould RE; Garcia AA
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
[TBL] [Abstract][Full Text] [Related]
5. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
6. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Ryan PD; Goss PE
Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Gligorov J; Pritchard K; Goss P
Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
11. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
12. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
13. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
14. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
Monnier A
Cancer Treat Rev; 2006 Nov; 32(7):532-40. PubMed ID: 16978789
[TBL] [Abstract][Full Text] [Related]
16. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
17. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
Burdette-Radoux S; Muss HB
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
[TBL] [Abstract][Full Text] [Related]
18. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Del Mastro L; Clavarezza M; Venturini M
Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
[TBL] [Abstract][Full Text] [Related]
20. Menopausal symptoms and adjuvant therapy-associated adverse events.
Hadji P
Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
